AGEs, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy

Marie-Paule Wautier; Eric Boulanger; Pierre-Jean Guillausseau; Pascale Massin; Jean-Luc Wautier

doi:10.1160/TH03-07-0486

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 91(05): 879-885
DOI: 10.1160/TH03-07-0486

Rapid and Short Communication

Schattauer GmbH

AGEs, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy

Marie-Paule Wautier

¹Institut National de la Transfusion Sanguine, Département de Biologie Cellulaire, Université Paris

²Institut National de la Transfusion Sanguine, INSERM U76, Hôpital Lariboisière, Paris, France

,

Eric Boulanger

¹Institut National de la Transfusion Sanguine, Département de Biologie Cellulaire, Université Paris

,

Pierre-Jean Guillausseau

³Institut National de la Transfusion Sanguine, Département de Médecine et, Hôpital Lariboisière, Paris, France

,

Pascale Massin

⁴Institut National de la Transfusion Sanguine, Ophthalmologie, Hôpital Lariboisière, Paris, France

,

Jean-Luc Wautier

¹Institut National de la Transfusion Sanguine, Département de Biologie Cellulaire, Université Paris

› Author Affiliations

Abstract

Summary

In vitro experiments and animal models indicate that advanced glycation end products (AGEs) may play a crucial role in the vascular dysfunctions observed in patients with diabetes mellitus. These results prompted us to study subrogate markers of inflammation or vascular dysfunction in type II diabetic patients. Monocyte count and activation are dependent upon macrophage colony stimulating factors (M-CSF). Soluble vascular cell adhesion molecule (sVCAM-1) blood levels have been proposed as a marker for endothelium activation. To explore a possible relationship between these factors in diabetic patients, we measured a chemically defined AGE, N(carboxymethyl)lysineprotein (CML-protein) in a group of normal subjects (n = 55) and of diabetic patients (n = 40) using ELISA. Simultaneously, we determined M-CSF and sVCAM-1 blood levels. We found that CML-protein blood levels were significantly higher in patients with diabetes compared to non-diabetic subjects (40.2 ± 4.7 and 7.9 ± 0.7 pmol/mg protein respectively, p < 0.0001). M-CSF was increased while sVCAM-1 blood levels were normal in the group of diabetics. M-CSF blood level was correlated to CML-protein blood level (p < 0.05). In addition CML-protein, M-CSF and sVCAM-1 were increased in patients with microangiopathy. These results suggest that AGE may contribute to vascular dysfunction including microangiopathy.

Keywords

Advanced glycation end products - carboxymethyl-lysine - macrophage colony stimulating factor and adhesion molecules

Full Text

References

References
1 Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-42.
2 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
3 Schmidt AM, Yan SD, Wautier JL. et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97.
4 Setiadi H, Wautier JL, Courillon-Mallet A. et al. Increased adhesion to fibronectin and MO-1 expression by diabetic monocytes. J Immunol 1987; 138: 3230-4.
5 Massin P, Angioi-Duprez K, Bacin F. et al. Detection, monitoring and treatment of diabetic retinopathy. Recommendations of ALFEDIAM. Committee of above mentioned experts and validated by the board of directors and scientific board of ALFEDIAM. Diabetes Metab 1996; 22: 203-9.
6 Wautier JL, Paton RC, Wautier MP. et al. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications. N Engl J Med 1981; 305: 237-42.
7 Guillausseau PJ, Fontbonne A, Cahen-Varsaux J. et al. Creatinine clearance evaluation in routine diabetes practice. Diabetes Res 1988; 07: 145-8.
8 Schmidt AM, Vianna M, Gerlach M. et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-97.
9 Kislinger T, Fu C, Huber B. et al. N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling path-ways and modulate gene expression. J Biol Chem 1999; 274: 31740-9.
10 Habeeb AF. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 1966; 14: 328-36.
11 Odani H, Matsumoto Y, Shinzato T. et al. Mass spectrometric study on the protein chemical modification of uremic patients in advanced Maillard reaction. J Chromatogr B Biomed Sci Appl 1999; 731: 131-40.
12 Burger D, Ramus MA, Schapira M. Antibodies to human plasma kallikrein from egg yolks of an immunized hen: preparation and characterization. Thromb Res 1985; 40: 283-8.
13 Polson A, Coetzer T, Kruger J. et al. Improvements in the isolation of IgY from the yolks of eggs laid by immunized hens. Immunol Invest 1985; 14: 323-7.
14 Wautier MP, Massin P, Guillausseau PJ. et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 2003; 29: 44-52.
15 Wautier JL, Wautier MP. Adhesion molecules in diabetic vasculopathy. In: Vascular Protection. Rubanyi GM, Dzau JD, Cooke JP. eds: Taylor & Francis Books; London: 2002: 135-140.
16 Abordo EA, Westwood ME, Thornalley PJ. Synthesis and secretion of macrophage colony stimulating factor by mature human monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucosederived advanced glycation endproducts. Immunol Lett 1996; 53: 7-13.
17 Schmidt AM, Yan SD, Yan SF. et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-55.
18 Wautier JL, Zoukourian C, Chappey O. et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hypermeability in diabetic rats. J Clin Invest 1996; 97: 238-43.
19 Park L, Raman KG, Lee KJ. et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endprodutcs. Nat Med 1998; 04: 1025-31.
20 Vlassara H, Fuh H, Donnelly T. et al. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995; 01: 447-56.
21 Zhou Z, Wang K, Penn MS. et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003; 107: 2238-43.
22 Cipollone F, Iezzi A, Fazia M. et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003; 108: 1070-7.
23 Tamarat R, Silvestre JS, Huijberts M. et al. Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Natl Acad Sci USA 2003; 100: 8555-60.
24 Wautier MP, Chappey O, Corda S. et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: 685-94.
25 Hammes HP, Du X, Edelstein D. et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 09: 294-9.